

# **Assessment Of Tissue CD4<sup>+</sup> Foxp3 And CD8<sup>+</sup> T-Cells In Non Segmental Vitiligo**

Thesis

Submitted for Partial Fulfillment of the Master Degree in  
Dermatology, Venereology and Andrology

Presented by

**Riham Mohamed Galal**

M.B, B.CH, Ain Shams University

Under Supervision of

**Prof. Dr. Marwa M.A. Abdallah**

Professor of Dermatology, Venereology and Andrology

Faculty of Medicine, Ain Shams University

**Prof. Dr. Ranya Adel Lotfi**

Assistant Professor of Dermatology, Venereology and Andrology

Faculty of Medicine, Ain Shams University

**Faculty of Medicine**

**Ain Shams University**

**2011**

# تقييم الخلايا الليمفاوية ت CD4<sup>+</sup> CD8<sup>+</sup> FoxP3 في الأنسجة في حالات البهاق المنتشر

رسالة توطئة للحصول علي درجة الماجستير في  
الأمراض الجلدية و التناسلية و أمراض الذكورة

مقدمة من

**الطبيبة/ ريهام محمد جلال**  
بكالوريوس الطب و الجراحة

تحت إشراف

**الأستاذة الدكتورة/ مروي عبد الرحيم عبد الله**  
أستاذ الأمراض الجلدية و التناسلية و أمراض الذكورة  
كلية الطب جامعة عين شمس

**الأستاذة الدكتورة/ رانية عادل لطفى**  
أستاذ مساعد الأمراض الجلدية و التناسلية و أمراض الذكورة  
كلية الطب جامعة عين شمس

**كلية الطب**  
**جامعة عين شمس**

# ACKNOWLEDGEMENT

I would like to express my sincere gratitude to

***Prof. Dr. Marwa M.A Abdallah*** Professor of Dermatology venereology and Andrology, Ain Shams University, who devoted much of his precious time, kind guidance and meticulous supervision.

I would like to thank

***Prof. Dr. Ranya Adel Lotfi***

Assistant Professor of Dermatology, venereology and Andrology, Ain Shams University for his sincere advice, generous help, kind guidance and meticulous supervision.

Special thanks to

***Prof. Dr. Wessam Mohamed Othman***

Assistant Professor of Pathology, Ain Shams University who has assisted me and supported me in the methodology and all the pathology work in this study.

Great thanks to

***Prof Dr.Ehab Shehad Habel***

Assistant Professor of community, Ain Shams University who has assisted me and supported me throughout the results and the statistical analysis of this study.

Last but not least, I would like to thank my parents, my husband, my sisters and friends for their constant support and encouragement.

Riham Mohamed Galal

2011

# CONTENTS

|                                                                    | <b>Page</b> |
|--------------------------------------------------------------------|-------------|
| Introduction                                                       | 1           |
| • Aim of the work                                                  | 4           |
| Review of literature                                               | 5           |
| • Chapter 1 (Vitiligo)                                             | 5           |
| • Chapter 2 (Immune mechanisms in the<br>pathogenesis of vitiligo) | 33          |
| Patients and methods                                               | 63          |
| Results                                                            | 73          |
| Discussion                                                         | 101         |
| Summary & conclusion                                               | 109         |
| References                                                         | 114         |
| Arabic summary                                                     | 155         |

# LIST OF FIGURES

| <b>Figure</b> | <b>Illustrating</b>                                                                   | <b>Page</b> |
|---------------|---------------------------------------------------------------------------------------|-------------|
| 1             | Vitiligo                                                                              | 8           |
| 2             | Multichrome vitiligo                                                                  | 11          |
| 3             | Melanocytorrhagy                                                                      | 29          |
| 4             | Cell-cell and cell-matrix adhesion                                                    | 32          |
| 5             | CD4 <sup>+</sup> and CD8 <sup>+</sup> T cells in L skin biopsy of active case of NSV  | 74          |
| 6             | CD4 <sup>+</sup> and CD8 <sup>+</sup> T cells in PL skin biopsy of stable case of NSV | 75          |
| 7             | Foxp3 in PL skin biopsy of active case of NSV                                         | 76          |
| 8             | Foxp3 in PL skin biopsy of stable case of NSV                                         | 77          |
| 9             | CD4 <sup>+</sup> and CD8 <sup>+</sup> T cells in L skin biopsy of active case of NSV  | 81          |
| 10            | CD4 <sup>+</sup> and CD8 <sup>+</sup> T cells in PL biopsy of an active case of NSV   | 82          |
| 11            | CD4 <sup>+</sup> and CD8 <sup>+</sup> T cells in L biopsy of an active case of NSV    | 84          |
| 12            | CD4 <sup>+</sup> and CD8 <sup>+</sup> T cells in PL biopsy of an stable case of NSV   | 85          |
| 13            | CD4 <sup>+</sup> and CD8 <sup>+</sup> T cells in cases of active and stable NSV       | 87          |

| <b>Figure</b> | <b>Illustrating</b>                                                                                             | <b>Page</b> |
|---------------|-----------------------------------------------------------------------------------------------------------------|-------------|
| 14            | FoxP3 in cases of active and stable NSV                                                                         | 89          |
| 15            | Comparison between active and stable NSV regarding CD4 <sup>+</sup> T cells                                     | 91          |
| 16            | Comparison between active and stable NSV regarding CD8 <sup>+</sup> T cells                                     | 91          |
| 17            | Comparison between active and stable NSV regarding CD4 <sup>+</sup> /CD8 <sup>+</sup> ratio                     | 92          |
| 18            | Comparison between active and stable NSV regarding FoxP3                                                        | 92          |
| 19            | CD4 <sup>+</sup> and CD8 <sup>+</sup> T cells in PL biopsy of an active case of NSV                             | 94          |
| 20            | FoxP3 in L skin in NSV                                                                                          | 95          |
| 21            | CD4 <sup>+</sup> , CD8 <sup>+</sup> T cells and FoxP3 in NL biopsy of active cases of NSV and in normal control | 98          |
| 22            | CD4 <sup>+</sup> , CD8 <sup>+</sup> T cells and FoxP3 in NL biopsy of stable cases of NSV and in normal control | 100         |

# LIST OF TABLES

| Table | Illustrating                                                                                                                                                     | Page |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| 1     | Prevalence of vitiligo in Egypt                                                                                                                                  | 5    |
| 2     | Melanogenic cytokines in NSV                                                                                                                                     | 41   |
| 3     | Melanocyte antigens in NSV                                                                                                                                       | 49   |
| 4     | Genes and genomic regions in NSV                                                                                                                                 | 58   |
| 5     | Personal characteristics of the study samples                                                                                                                    | 73   |
| 6     | Comparison between L, PL and NL of all cases of NSV regarding CD4 <sup>+</sup> , CD8 <sup>+</sup> T cells, FoxP3 and CD4 <sup>+</sup> /CD8 <sup>+</sup> ratio    | 78   |
| 7     | Comparison between L, PL and NL of active cases of NSV regarding CD4 <sup>+</sup> , CD8 <sup>+</sup> T cells, FoxP3 and CD4 <sup>+</sup> /CD8 <sup>+</sup> ratio | 80   |
| 8     | Comparison between L, PL and NL of stable cases of NSV regarding CD4 <sup>+</sup> , CD8 <sup>+</sup> T cells, FoxP3 and CD4 <sup>+</sup> /CD8 <sup>+</sup> ratio | 83   |
| 9     | Comparison between active and stable cases of NSV regarding CD4 <sup>+</sup> , CD8 <sup>+</sup> T cells, FoxP3 and CD4 <sup>+</sup> /CD8 <sup>+</sup> ratio      | 86   |

| <b>Table</b> | <b>Illustrating</b>                                                                                                                   | <b>Page</b> |
|--------------|---------------------------------------------------------------------------------------------------------------------------------------|-------------|
| 10           | Comparison between CD4 <sup>+</sup> and CD8 <sup>+</sup> T cells in epidermis and DEJ in both active and stable cases of NSV          | 93          |
| 11           | Comparison between NL skin of all cases of NSV and normal controls regarding CD4 <sup>+</sup> , CD8 <sup>+</sup> T cells and FoxP3    | 96          |
| 12           | Comparison between NL skin of active cases of NSV and normal controls regarding CD4 <sup>+</sup> , CD8 <sup>+</sup> T cells and FoxP3 | 97          |
| 13           | Comparison between NL skin of stable cases of NSV and normal controls regarding CD4 <sup>+</sup> , CD8 <sup>+</sup> T cells and FoxP3 | 99          |

# LIST OF ABBREVIATIONS

|        |                                          |
|--------|------------------------------------------|
| 6BH4   | Tetrahydrobiopetrin                      |
| ACTH   | Adrenocorticotrophic hormone             |
| ADCC   | Antibody dependent cellular cytotoxicity |
| AGRP   | Agouti related peptide                   |
| AP     | Alkaline phosphatase                     |
| APS1   | Autoimmune polyendocrine syndrome type 1 |
| ASIP   | Agouti signaling peptide                 |
| BC     | Before christ                            |
| Bcl-2  | B cell leukemia/lymphoma 2 gene          |
| BFGF   | Basic fibroblast growth factor           |
| B-FGFR | Basic fibroblast growth factor receptor  |
| BSA    | Body surface area                        |
| CCL    | Chemoattractant ligand                   |
| CCR    | Chemokine receptor                       |
| C-MET  | Proto antigen encodes HGF                |
| CTLA4  | Cytotoxic T lymphocyte antigen 4         |
| DC     | Dendritic cells                          |
| DCT    | Dopachrome tautomerase                   |
| DEJ    | Dermo-epidermal junction                 |
| DI     | Distilled water                          |

|                               |                                                       |
|-------------------------------|-------------------------------------------------------|
| DNA                           | Deoxyribonucleotide acid                              |
| DOPA                          | Dihydroxiphenolalanine                                |
| EDTA                          | Ethylenediaminetetraacetic acid                       |
| ET-1                          | Endothelin                                            |
| ETBR                          | Ethidium bromide                                      |
| FLIP                          | Flagellar biothynthesis protein gene                  |
| FOXP3                         | Forkhead box p3                                       |
| GITR                          | Glucocorticoid induced tumor necrosis factor receptor |
| GM-CSF                        | Granulocyte macrophage colony-stimulating factor      |
| H <sub>2</sub> O <sub>2</sub> | Hydrogen peroxide                                     |
| HGF                           | Hepatocyte growth factor                              |
| HIER                          | Heat induced epitope recovery                         |
| HLA                           | Human leukocyte antigen                               |
| HRP                           | Horseradish peroxidase                                |
| HSP                           | Heat shocked proteins                                 |
| ICAM                          | Intercellular adhesion molecules                      |
| IDDM                          | Insulin dependent diabetes mellitus                   |
| IFN- $\gamma$                 | Gamma interferon                                      |
| IgA                           | Immunoglobulin A                                      |
| IgG                           | Immunoglobulin G                                      |
| IL-6                          | Interleukin 6                                         |
| IPEX                          | Immunodysregulation polyendocrinopathy                |

|       |                                             |
|-------|---------------------------------------------|
|       | enteropathy x-linked syndrome               |
| KGf   | Keratinocyte growth factor                  |
| KGFR  | Keratinocyte growth factor receptor         |
| L     | Lesional                                    |
| LRP   | Leucine rich repeat                         |
| MART1 | Melanoma antigen recognized by T cells 1    |
| MC    | Melanocortin                                |
| MCHR1 | Melanin concentrating hormone receptor 1    |
| MCI-R | Melanocortin Receptor                       |
| MHC   | Major histocompatibility complex            |
| mRNA  | Messenger ribonucleotide acid               |
| MSH   | Melanocyte stimulating hormone              |
| NACHT | Neural apoptosis inhibitory protein         |
| NADPH | Nicotinamide adenine dinucleotide phosphate |
| NALP1 | NACT,LRP- and PYD containing proteins       |
| NK    | Natural killer cells                        |
| NL    | Non lesional                                |
| NSV   | Non- segmental vitiligo                     |
| PAH   | Polycyclic aromatic hydrocarbon             |
| PBMCS | Peripheral blood mononuclear cells          |
| PBS   | Protein blocking serum                      |
| PCR   | Polymerase chain reaction                   |

|               |                                       |
|---------------|---------------------------------------|
| PL            | Perilesional                          |
| Pmel17        | Melanosomal matrix protein            |
| POMC          | Proopiomelanocortin                   |
| PYD           | Pyurin N-terminal homology domain     |
| ROS           | Reactive oxygen species               |
| SCF           | Stem cell factor                      |
| SNPs          | Single nucleotide polymorphism        |
| SOX           | Sex determining region y -box         |
| TBST          | Tris buffered saline +0.1 % tween 20  |
| TGF- $\beta$  | Transforming growth factor beta       |
| Th            | T helper cells                        |
| TNF- $\gamma$ | Tumor necrosis factor gamma           |
| TRAIL         | TNF-related apoptosis-inducing ligand |
| Tregs         | T regulatory cells                    |
| TRP           | Transient receptor potential channel  |
| TYRP1         | Tyrosinase related protein 1          |
| UV            | Ultra violet                          |
| UVB           | Ultra violet band                     |

# INTRODUCTION

Vitiligo is a depigmenting disorder characterized by the loss of melanocytes from the epidermis. It strikes approximately 0.5-1% of the world population (**Taieb et al., 2007**). Although the exact etiology of vitiligo has not yet been established, an autoimmune component plays a major role in its pathogenesis. In progressive disease the CD4<sup>+</sup>/CD8<sup>+</sup> ratio is decreased among skin-infiltrating T cells and CD8<sup>+</sup> T cells isolated from vitiligo skin are cytotoxic to melanocytes (**Wankowicz-Kalinska et al., 2003**).

Cytotoxic T cells require CD4<sup>+</sup>T cell help to be activated against melanocytes (**Steitz et al., 2005**). Involved helper and cytotoxic T cells from progressing vitiligo margins generate predominantly type 1 cytokines, namely, interferon (IFN)- $\gamma$  and tumor necrosis factor (TNF)- $\alpha$  suggesting that vitiligo is a Th1-mediated disease (**Le Poole et al., 2004**). Autoimmunity results from unchecked control by regulatory T-cells (Tregs), although the exact reason for autoimmune diseases is not yet fully elucidated (**Levings et al., 2001**).

Native CD4<sup>+</sup> helper T cells are known to develop into at least 4 types, namely-helper 1(Th1), Th2, Th17, and regulatory T cells (Tregs). Th1 cells primarily produce IFN- $\gamma$  and TNF- $\alpha$  ;Th2 cells synthesize interleukin ( IL)-4, IL-5, IL-13 ; Th17 cells produce IL-17 and IL-6; and Tregs synthesize IL10 and transforming growth factor ( TGF )- $\beta$  (*Ortonne et al., 2003* ).

Markers expressed by Tregs include FoxP3, GITR, CTLA-4 and CD25, yet only FoxP3 expression is relatively unique to regulatory T cells (*De Boer et al., 2007*). FoxP3 is the acronym given to the forkhead winged-helix transcription factor “forkhead box P3” which serves as the dedicated mediator of the genetic program governing Tregs development and function; therefore it is regarded as a reliable and specific marker for Tregs (*Hori, 2003; Yagi et al., 2004*).

Tregs have several immunomodulatory effects such as an anti-inflammatory role to maintain tolerance to self–antigens. In addition, Tregs have the ability to inhibit the responses of CD8<sup>+</sup> T cells, natural killer cells and CD4<sup>+</sup> T cells, so that Tregs may be important in the prevention of autoimmune diseases (*Afzali et al., 2007*).

The role of Tregs in the pathogenesis of vitiligo is still disputable because some authors say that the serum level of Tregs increase (*Abdallah et al., 2009*). Others revealed that The percentage of CD8<sup>+</sup> T cells was significantly increased in vitiligo group compared with the controls and no difference was detected between the patients and control groups in percentages of CD4<sup>+</sup> T cells (*Basak et al., 2008*) While others revealed no systemic drop in the abundance or activity of Tregs in vitiligo patients and also reported the percentage of Tregs among skin infiltrating T cells are drastically reduced in non-lesional, perilesional and lesional vitiligo skin (*Klarquist et al., 2010*).